Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Pemetrexed + Carboplatin vs Etoposide + Carboplatin in Extensive-Stage Small Cell Lung Cancer
2006-001173-14Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in small cell lung cancer (SCLC) comparing Pemetrexed (Alimta) + carboplatin with Etoposide + carboplatin (2 arms). Primary endpoint: Overall survival. Started May 2006; status: completed.
02
Drugs
pemetrexedcarboplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2006-001173-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001173-14.